MeiraGTx Holdings plc Finance Lease, Right-of-Use Asset, after Accumulated Amortization
MeiraGTx Holdings plc (MGTX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $22.42 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $22.42M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $22.83M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $23.62M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $23.80M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $22.42M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $22.83M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $23.62M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $23.80M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $24.15M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $22.73M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $22.20M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $24.11M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $23.29M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $23.69M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $24.43M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $23.68M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $24.63M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $24.85M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $24.72M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $22.89M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $24.77M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $26.77M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $27.64M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $28.43M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $29.49M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $29.45M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $21.60M 10-K · filed 2022-03-10 | $21.60M 10-K · filed 2021-03-11 |
| 2020-09-30 | $20.52M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $6.49M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $6.61M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $7.14M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $6.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $6.97M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $7.26M 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |